$11.00
00.00%
Pre-Market: Jul 19, 4:04 PM EDT
15 minutes delayed
Comments
Loading...
Roivant Sciences
ROIVNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Roivant Sciences (NASDAQ:ROIV) Stock, Analyst Ratings, Price Targets, Forecasts
Roivant Sciences Ltd has a consensus price target of $15.46 based on the ratings of 15 analysts. The high is $23 issued by Truist Securities on March 25, 2024. The low is $10 issued by SVB Leerink on December 19, 2022. The 3 most-recent analyst ratings were released by Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co. on July 10, 2024, May 31, 2024, and April 22, 2024, respectively. With an average price target of $19.33 between Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 75.76% upside for Roivant Sciences Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Goldman Sachs
Deutsche Bank
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Roivant Sciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 100% | Piper Sandler | Allison Bratzel | $20 → $22 | Maintains | Overweight | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 05/31/2024 | Buy Now | 63.64% | HC Wainwright & Co. | Douglas Tsao | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 04/22/2024 | Buy Now | 63.64% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 63.64% | Goldman Sachs | Corinne Jenkins | $16 → $18 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | 63.64% | HC Wainwright & Co. | Douglas Tsao | $17 → $18 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | 36.36% | Deutsche Bank | Neena Bitritto-Garg | $14 → $15 | Maintains | Buy | Get Alert |
| 03/25/2024 | Buy Now | 109.09% | Truist Securities | Robyn Karnauskas | → $23 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | Buy Now | 54.55% | Wolfe Research | Andy Chen | → $17 | Initiates | → Outperform | Get Alert |
| 02/14/2024 | Buy Now | 54.55% | HC Wainwright & Co. | Douglas Tsao | $18 → $17 | Maintains | Buy | Get Alert |
| 01/05/2024 | Buy Now | 81.82% | Piper Sandler | Allison Bratzel | → $20 | Initiates | → Overweight | Get Alert |
| 01/02/2024 | Buy Now | 9.09% | B of A Securities | Chi Fong | $11 → $12 | Maintains | Neutral | Get Alert |
| 12/12/2023 | Buy Now | 27.27% | Deutsche Bank | Neena Bitritto-Garg | → $14 | Initiates | → Buy | Get Alert |
| 11/15/2023 | Buy Now | 45.45% | Guggenheim | Yatin Suneja | $17 → $16 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | 36.36% | JP Morgan | Brian Cheng | $16 → $15 | Maintains | Overweight | Get Alert |
| 10/17/2023 | Buy Now | 54.55% | Guggenheim | Yatin Suneja | → $17 | Initiates | → Buy | Get Alert |
| 09/27/2023 | Buy Now | 45.45% | Goldman Sachs | Corinne Jenkins | $14 → $16 | Maintains | Buy | Get Alert |
| 09/26/2023 | Buy Now | 109.09% | Truist Securities | Robyn Karnauskas | → $23 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | Buy Now | 36.36% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2023 | Buy Now | 36.36% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 08/31/2023 | Buy Now | 36.36% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 36.36% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | Buy Now | 63.64% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
| 07/14/2023 | Buy Now | 109.09% | Truist Securities | Robyn Karnauskas | → $23 | Reiterates | Buy → Buy | Get Alert |
| 06/29/2023 | Buy Now | 63.64% | HC Wainwright & Co. | Douglas Tsao | $15 → $18 | Maintains | Buy | Get Alert |
| 06/23/2023 | Buy Now | 109.09% | Truist Securities | Robyn Karnauskas | $19 → $23 | Maintains | Buy | Get Alert |
| 06/23/2023 | Buy Now | 36.36% | HC Wainwright & Co. | Douglas Tsao | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | 36.36% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 06/08/2023 | Buy Now | -4.55% | B of A Securities | Chi Fong | → $10.5 | Initiates | → Neutral | Get Alert |
| 05/18/2023 | Buy Now | 27.27% | JP Morgan | Brian Cheng | $12 → $14 | Maintains | Overweight | Get Alert |
| 05/17/2023 | Buy Now | 36.36% | HC Wainwright & Co. | Douglas Tsao | $14 → $15 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 27.27% | HC Wainwright & Co. | Douglas Tsao | → $14 | Reiterates | Buy → Buy | Get Alert |
| 03/29/2023 | Buy Now | 9.09% | JP Morgan | Brian Cheng | → $12 | Maintains | Overweight | Get Alert |
| 03/16/2023 | Buy Now | 27.27% | HC Wainwright & Co. | Douglas Tsao | → $14 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | 27.27% | HC Wainwright & Co. | Douglas Tsao | → $14 | Reiterates | → Buy | Get Alert |
| 02/13/2023 | Buy Now | — | JP Morgan | Brian Cheng | $10 → $11 | Maintains | Overweight | Get Alert |
| 01/19/2023 | Buy Now | — | Goldman Sachs | Corinne Jenkins | $10 → $11 | Maintains | Buy | Get Alert |
| 01/10/2023 | Buy Now | -9.09% | JP Morgan | Brian Cheng | $9 → $10 | Maintains | Overweight | Get Alert |
| 01/05/2023 | Buy Now | 27.27% | Citigroup | Neena Bitritto-Garg | $11 → $14 | Maintains | Buy | Get Alert |
| 12/19/2022 | Buy Now | -9.09% | SVB Leerink | David Risinger | $8 → $10 | Maintains | Outperform | Get Alert |
| 12/12/2022 | Buy Now | -18.18% | JP Morgan | Brian Cheng | → $9 | Maintains | Overweight | Get Alert |
| 11/15/2022 | Buy Now | — | Citigroup | Neena Bitritto-Garg | $10 → $11 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | -27.27% | SVB Leerink | David Risinger | $7 → $8 | Maintains | Outperform | Get Alert |
| 08/16/2022 | Buy Now | -9.09% | Citigroup | Neena Bitritto-Garg | $9 → $10 | Maintains | Buy | Get Alert |
| 06/29/2022 | Buy Now | -36.36% | SVB Leerink | David Risinger | $6 → $7 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | 9.09% | Goldman Sachs | Corinne Jenkins | $15 → $12 | Maintains | Buy | Get Alert |
| 05/23/2022 | Buy Now | -45.45% | SVB Leerink | David Risinger | → $6 | Initiates | → Outperform | Get Alert |
| 04/29/2022 | Buy Now | 36.36% | Cantor Fitzgerald | Louise Chen | → $15 | Initiates | → Overweight | Get Alert |
| 12/15/2021 | Buy Now | 36.36% | Goldman Sachs | Corinne Jenkins | — | Initiates | → Buy | Get Alert |
| 11/08/2021 | Buy Now | 27.27% | HC Wainwright & Co. | Douglas Tsao | — | Initiates | → Buy | Get Alert |
| 11/01/2021 | Buy Now | — | SVB Leerink | Geoffrey Porges | — | Initiates | → Outperform | Get Alert |
| 10/26/2021 | Buy Now | -9.09% | Jefferies | Dennis Ding | — | Initiates | → Buy | Get Alert |
| 10/26/2021 | Buy Now | — | Cowen & Co. | Yaron Werber | — | Initiates | → Outperform | Get Alert |
| 10/26/2021 | Buy Now | 36.36% | Truist Securities | Robyn Karnauskas | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Roivant Sciences (ROIV) stock?
The latest price target for Roivant Sciences (NASDAQ:ROIV) was reported by Piper Sandler on July 10, 2024. The analyst firm set a price target for $22.00 expecting ROIV to rise to within 12 months (a possible 100.00% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Roivant Sciences (ROIV)?
The latest analyst rating for Roivant Sciences (NASDAQ:ROIV) was provided by Piper Sandler, and Roivant Sciences maintained their overweight rating.
When was the last upgrade for Roivant Sciences (ROIV)?
There is no last upgrade for Roivant Sciences
When was the last downgrade for Roivant Sciences (ROIV)?
There is no last downgrade for Roivant Sciences.
When is the next analyst rating going to be posted or updated for Roivant Sciences (ROIV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Roivant Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Roivant Sciences was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Roivant Sciences (ROIV) correct?
While ratings are subjective and will change, the latest Roivant Sciences (ROIV) rating was a maintained with a price target of $20.00 to $22.00. The current price Roivant Sciences (ROIV) is trading at is $11.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.